权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chromophobe renal cell carcinoma: establishment of a new diagnostic and prognostic grading system

嫌色肾细胞癌：建立新的诊断和预后分级系统

基本信息

批准号：
275904863
负责人：
Privatdozentin Dr. Franziska Erlmeier
金额：
--
依托单位：
Pathologisches Institut
依托单位国家：
德国
项目类别：
Research Grants
财政年份：
2015
资助国家：
德国
起止时间：
2014-12-31 至 2018-12-31
项目状态：
已结题

来源：
https://gepris.dfg.de/gepris/projekt/275904863?language=en
关键词：
Chromophobe renal cell carcinoma establishment

项目摘要

Chromophobe renal cell carcinoma (ChRCC) is one of four malignant renal tumour subtypes. Because of its morphological variation, ChRCC repeatedly presents problems in routine pathological diagnosis. The tumour can be mistaken for more aggressive and for benign tumours. In both cases, the effects of the incorrect diagnosis on treatment decisions are grave.Due to the morphological variation of the tumour, development of a generally recognised grading system that is prognostically reliable has so far been unsuccessful. In this project, such a grading system for ChRCC will be developed. For this, new diagnostic biomarkers will be measured for distinguishing the tumour better from other subtypes. In addition, new prognostic biomarkers will be developed for more effective estimation of the clinical course. By studying nuclear membrane proteins as the link between morphological and chromosomal changes, I expect to discover new biomarkers that will be valuable for diagnosis and prognosis. These aims will be achieved by combining established methods (e.g., immunohistochemical stainings, fluorescence in situ hybridisations) with newer methods (e.g., morphometry, mass spectrometry).The aim of this project is to better distinguish ChRCC from other tumour subtypes using a new grading system and thus optimise patient care.

肾嫌色细胞癌（ChRCC）是肾脏恶性肿瘤的四种亚型之一。由于其形态变异，ChRCC在常规病理诊断中反复出现问题。这种肿瘤可能被误认为是更具侵略性的良性肿瘤。在这两种情况下，不正确的诊断对治疗决策的影响是严重的。由于肿瘤的形态变化，迄今为止，开发一个普遍认可的分级系统，是解剖学上可靠的是不成功的。在本项目中，将为ChRCC开发这样的分级系统。为此，将测量新的诊断生物标志物，以更好地区分肿瘤与其他亚型。此外，将开发新的预后生物标志物，以更有效地估计临床过程。通过研究核膜蛋白作为形态学和染色体变化之间的联系，我希望发现新的生物标志物，这将是有价值的诊断和预后。这些目标将通过结合既定方法（例如，免疫组织化学染色，荧光原位杂交）与较新的方法（例如，该项目的目的是使用新的分级系统更好地区分ChRCC与其他肿瘤亚型，从而优化患者护理。